MA34252B1 - Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes - Google Patents
Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenesInfo
- Publication number
- MA34252B1 MA34252B1 MA35399A MA35399A MA34252B1 MA 34252 B1 MA34252 B1 MA 34252B1 MA 35399 A MA35399 A MA 35399A MA 35399 A MA35399 A MA 35399A MA 34252 B1 MA34252 B1 MA 34252B1
- Authority
- MA
- Morocco
- Prior art keywords
- present
- disorders
- tetraazabenzo
- azulenes
- heteroaryl
- Prior art date
Links
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical class C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010001488 Aggression Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 abstract 1
- 102000002852 Vasopressins Human genes 0.000 abstract 1
- 108010004977 Vasopressins Proteins 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 208000012761 aggressive behavior Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 150000001545 azulenes Chemical class 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960003726 vasopressin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE DES HÉTÉROARYL-CYCLOHEXYL-TÉTRAAZABENZO[E]AZULÈNES DE FORMULE (I) DANS LAQUELLE R1, R2 ET R3 SONT TELS QUE DÉCRITS DANS LE PRÉSENT DOCUMENT. LES COMPOSÉS SELON L'INVENTION AGISSENT VIA LES MODULATEURS DES RÉCEPTEURS, ET EN PARTICULIER VIA LES ANTAGONISTES DES RÉCEPTEURS. LA PRÉSENTE INVENTION CONCERNE EN OUTRE LEUR FABRICATION, DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS. LES COMPOSÉS ACTIFS DE LA PRÉSENTE INVENTION SONT UTILES EN TANT QUE PRODUITS THÉRAPEUTIQUES À ACTION PÉRIPHÉRIQUE ET CENTRALE DANS LES CONDITIONS SUIVANTES : DYSMÉNORRHÉES, DYSFONCTION SEXUELLE CHEZ L'HOMME OU CHEZ LA FEMME, HYPERTENSION, INSUFFISANCE CARDIAQUE CHRONIQUE, SÉCRÉTION DE VASOPRESSINE INADAPTÉE, CIRRHOSE HÉPATIQUE, SYNDROME NÉPHROTIQUE, ANXIÉTÉ, TROUBLES DÉPRESSIFS, TROUBLE OBSESSIONNEL COMPULSIF, TROUBLES DU SPECTRE DE L'AUTISME, SCHIZOPHRÉNIE, ET COMPORTEMENT AGRESSIF.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10162451 | 2010-05-10 | ||
| PCT/EP2011/057368 WO2011141396A1 (fr) | 2010-05-10 | 2011-05-09 | Hétéroaryl-cyclohexyl-tétraazabenzo[e]azulènes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34252B1 true MA34252B1 (fr) | 2013-05-02 |
Family
ID=44080459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35399A MA34252B1 (fr) | 2010-05-10 | 2011-05-09 | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US8513238B2 (fr) |
| EP (1) | EP2569319B1 (fr) |
| JP (1) | JP5868959B2 (fr) |
| KR (1) | KR20130109958A (fr) |
| CN (1) | CN102884065B (fr) |
| AR (1) | AR081374A1 (fr) |
| AU (1) | AU2011252116B2 (fr) |
| BR (1) | BR112012028763A2 (fr) |
| CA (1) | CA2797920A1 (fr) |
| CL (1) | CL2012003132A1 (fr) |
| CO (1) | CO6620058A2 (fr) |
| CR (1) | CR20120542A (fr) |
| CY (1) | CY1115820T1 (fr) |
| DK (1) | DK2569319T3 (fr) |
| EA (1) | EA021441B1 (fr) |
| EC (1) | ECSP12012291A (fr) |
| ES (1) | ES2523881T3 (fr) |
| HR (1) | HRP20141250T1 (fr) |
| IL (1) | IL222815A (fr) |
| MA (1) | MA34252B1 (fr) |
| MX (1) | MX2012012857A (fr) |
| MY (1) | MY160517A (fr) |
| NZ (1) | NZ603223A (fr) |
| PE (1) | PE20130401A1 (fr) |
| PH (1) | PH12012502174A1 (fr) |
| PL (1) | PL2569319T3 (fr) |
| PT (1) | PT2569319E (fr) |
| RS (1) | RS53669B1 (fr) |
| SG (1) | SG185484A1 (fr) |
| SI (1) | SI2569319T1 (fr) |
| TW (1) | TWI419892B (fr) |
| UA (1) | UA110616C2 (fr) |
| WO (1) | WO2011141396A1 (fr) |
| ZA (1) | ZA201208317B (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009315754B2 (en) | 2008-11-13 | 2013-08-15 | F. Hoffmann-La Roche Ag | Spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes |
| PE20110590A1 (es) | 2008-11-18 | 2011-08-31 | Hoffmann La Roche | Alquilciclohexileteres de dihidrotetraazabenzoazulenos |
| BRPI0922303B1 (pt) | 2008-11-28 | 2019-11-12 | Hoffmann La Roche | arilciclo-hexiléteres de di-hidrotetra-azabenzoazulenos, seu processo de preparação, composição farmacêutica que os compreende e uso |
| US8420633B2 (en) | 2010-03-31 | 2013-04-16 | Hoffmann-La Roche Inc. | Aryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8461151B2 (en) | 2010-04-13 | 2013-06-11 | Hoffmann-La Roche Inc. | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes |
| US8492376B2 (en) | 2010-04-21 | 2013-07-23 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8481528B2 (en) | 2010-04-26 | 2013-07-09 | Hoffmann-La Roche Inc. | Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8513238B2 (en) | 2010-05-10 | 2013-08-20 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes |
| WO2017191117A1 (fr) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Antagonistes du récepteur v1a destinés à une utilisation dans le traitement de maladies rénales |
| TW201837026A (zh) | 2017-01-10 | 2018-10-16 | 德商拜耳廠股份有限公司 | 作為除害劑之雜環衍生物（二） |
| KR102515694B1 (ko) | 2017-01-10 | 2023-03-29 | 바이엘 악티엔게젤샤프트 | 해충 방제제로서의 헤테로사이클 유도체 |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| TW201938171A (zh) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物 |
| WO2020182649A1 (fr) | 2019-03-08 | 2020-09-17 | Syngenta Crop Protection Ag | Composés azole-amide à action pesticide |
| JP7549601B2 (ja) | 2019-03-20 | 2024-09-11 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物活性アゾールアミド化合物 |
| CN114644635B (zh) * | 2020-12-21 | 2023-02-03 | 上海济煜医药科技有限公司 | 三氮唑类三并环衍生物及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5428157A (en) | 1993-11-22 | 1995-06-27 | Merck & Co., Inc. | 3-acylaminobenzodiazepines |
| NL9401174A (nl) | 1994-07-15 | 1996-02-01 | A P I S Medical Bv | Inspuitsamenstel met opzuignaald en terugtrekbare inspuitnaald. |
| IL133788A0 (en) * | 1997-07-30 | 2001-04-30 | American Home Prod | Tricyclic vasopressin agonists |
| TR200102069T2 (tr) | 1999-01-19 | 2001-11-21 | Ortho-Mcneil Pharmaceutical, Inc. | Vasopresin reseptörü antagonistleri olarak trisiklik benzodiazepinler. |
| US7109193B2 (en) | 2001-04-12 | 2006-09-19 | Wyeth | Tricyclic diazepines tocolytic oxytocin receptor antagonists |
| US7022699B2 (en) | 2001-04-12 | 2006-04-04 | Wyeth | Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators |
| AU2003212979A1 (en) | 2002-02-07 | 2003-09-02 | Neurogen Corporation | Substituted fused pyrazolecarboxylic acid arylamides and related compounds |
| GB0303852D0 (en) * | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
| GB0400700D0 (en) | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
| GEP20094723B (en) | 2004-05-25 | 2009-07-10 | Pfizer Prod Inc | Tetraazabenzo [e] azulene derivatives and analogs thereof |
| KR100840852B1 (ko) | 2004-05-25 | 2008-06-23 | 화이자 프로덕츠 인크. | 테트라아자벤조[ｅ]아줄렌 유도체 및 이의 유사체 |
| EP1632494A1 (fr) | 2004-08-24 | 2006-03-08 | Ferring B.V. | Antagonistes de la v1a vasopressine |
| BRPI0514458A (pt) | 2004-08-25 | 2008-06-10 | Pfizer | triazolbenzodiazepinas e seu uso como antagonistas de vasopressina |
| CA2577937C (fr) * | 2004-08-26 | 2010-12-21 | Pfizer Inc. | Composes aminoheteroaryle a substitution pyrazole servant d'inhibiteurs de proteine kinase |
| JP2008539220A (ja) | 2005-04-26 | 2008-11-13 | ファイザー・リミテッド | バソプレシンアンタゴニストとしてのトリアゾール誘導体 |
| EP1885713A1 (fr) | 2005-05-18 | 2008-02-13 | Pfizer Limited | Derives de 1, 2, 4-triazole en tant qu'antagonistes de la vasopressine |
| WO2008084005A1 (fr) | 2007-01-12 | 2008-07-17 | F. Hoffmann-La Roche Ag | Dérivés de spiropipéridine glycinamide |
| PE20110590A1 (es) | 2008-11-18 | 2011-08-31 | Hoffmann La Roche | Alquilciclohexileteres de dihidrotetraazabenzoazulenos |
| US8420633B2 (en) | 2010-03-31 | 2013-04-16 | Hoffmann-La Roche Inc. | Aryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8461151B2 (en) | 2010-04-13 | 2013-06-11 | Hoffmann-La Roche Inc. | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes |
| US8492376B2 (en) | 2010-04-21 | 2013-07-23 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8481528B2 (en) | 2010-04-26 | 2013-07-09 | Hoffmann-La Roche Inc. | Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8513238B2 (en) | 2010-05-10 | 2013-08-20 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes |
-
2011
- 2011-05-05 US US13/101,173 patent/US8513238B2/en not_active Expired - Fee Related
- 2011-05-09 KR KR1020127032241A patent/KR20130109958A/ko not_active Ceased
- 2011-05-09 ES ES11718393.9T patent/ES2523881T3/es active Active
- 2011-05-09 EA EA201291187A patent/EA021441B1/ru not_active IP Right Cessation
- 2011-05-09 WO PCT/EP2011/057368 patent/WO2011141396A1/fr not_active Ceased
- 2011-05-09 DK DK11718393.9T patent/DK2569319T3/da active
- 2011-05-09 MY MYPI2012004887A patent/MY160517A/en unknown
- 2011-05-09 BR BR112012028763A patent/BR112012028763A2/pt not_active IP Right Cessation
- 2011-05-09 PL PL11718393T patent/PL2569319T3/pl unknown
- 2011-05-09 MA MA35399A patent/MA34252B1/fr unknown
- 2011-05-09 AR ARP110101587A patent/AR081374A1/es unknown
- 2011-05-09 SI SI201130313T patent/SI2569319T1/sl unknown
- 2011-05-09 AU AU2011252116A patent/AU2011252116B2/en not_active Ceased
- 2011-05-09 CA CA2797920A patent/CA2797920A1/fr not_active Abandoned
- 2011-05-09 JP JP2013509524A patent/JP5868959B2/ja not_active Expired - Fee Related
- 2011-05-09 PE PE2012002147A patent/PE20130401A1/es not_active Application Discontinuation
- 2011-05-09 CN CN201180023289.3A patent/CN102884065B/zh not_active Expired - Fee Related
- 2011-05-09 PH PH1/2012/502174A patent/PH12012502174A1/en unknown
- 2011-05-09 HR HRP20141250AT patent/HRP20141250T1/hr unknown
- 2011-05-09 TW TW100116207A patent/TWI419892B/zh not_active IP Right Cessation
- 2011-05-09 SG SG2012082483A patent/SG185484A1/en unknown
- 2011-05-09 EP EP11718393.9A patent/EP2569319B1/fr not_active Not-in-force
- 2011-05-09 MX MX2012012857A patent/MX2012012857A/es active IP Right Grant
- 2011-05-09 PT PT117183939T patent/PT2569319E/pt unknown
- 2011-05-09 NZ NZ603223A patent/NZ603223A/en not_active IP Right Cessation
- 2011-05-09 RS RS20140639A patent/RS53669B1/sr unknown
- 2011-09-05 UA UAA201213888A patent/UA110616C2/uk unknown
-
2012
- 2012-10-23 CR CR20120542A patent/CR20120542A/es unknown
- 2012-10-25 CO CO12191162A patent/CO6620058A2/es active IP Right Grant
- 2012-11-01 IL IL222815A patent/IL222815A/en active IP Right Grant
- 2012-11-05 ZA ZA2012/08317A patent/ZA201208317B/en unknown
- 2012-11-08 CL CL2012003132A patent/CL2012003132A1/es unknown
- 2012-11-09 EC ECSP12012291 patent/ECSP12012291A/es unknown
-
2014
- 2014-12-16 CY CY20141101044T patent/CY1115820T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34174B1 (fr) | Hetéroaryl-cyclohexyl-tétraazabenzo[e)azulènes comme antagonistes des récepteurs de la vasopressine v1a | |
| MA32781B1 (fr) | Arycyclohexylethers de dihydrotetrazabenzoazulenes pour emploi en tant qu'antagonistes du recepteur v1a de la vasopressine | |
| MA34173B1 (fr) | Hhétérobiaryl-cyclohexyl-tétraazabenzo[e]azulènes | |
| MA35246B1 (fr) | 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2 | |
| MA35191B1 (fr) | Spiro-[1,3]-oxazines et spiro-[1,4]-oxazepines en tant qu'inhibiteurs de baec1 et/ou bace2 | |
| MA34147B1 (fr) | Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales | |
| MA29411B1 (fr) | 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa | |
| MA35286B1 (fr) | Phényl-3-aza-bicyclo[3.1.0]hex-3-yl-méthanones et leur utilisation en tant que médicament | |
| MA35945B1 (fr) | Inhibiteurs de la bêta-sécrétase | |
| MA35193B1 (fr) | Halogeno-alkyl-1,3 oxazines en tant qu'inhibiteurs de bace1 et/ou bace2 | |
| MA38079A1 (fr) | Composés de 2-phényl-5-hétérocyclyl-tétrahydro-2h-pyran-3-amine destinés à être utilisés dans le traitement du diabète et de ses troubles associés | |
| MA37762B1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| MA34013B1 (fr) | Inhibiteurs du virus de l'hépatite c | |
| MA34898B1 (fr) | Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques | |
| EA201170705A1 (ru) | Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1 | |
| CO6620058A2 (es) | Heteroaril-ciclohexil-tetraazabenzo[e]azulenos | |
| MX2010005861A (es) | Agonistas novedosos de los receptores de glucocorticoides. | |
| TN2009000324A1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides | |
| MA20150429A1 (fr) | Benzamides | |
| IN2014CN02273A (fr) | ||
| EP2260851A4 (fr) | Utilisation d'un triterpène pentacyclique pour la préparation d'une composition pharmaceutique destinée au traitement de la sclérose en plaques | |
| IN2014CN02364A (fr) | ||
| MA34094B1 (fr) | Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2 | |
| MX2011012669A (es) | Nuevos agonistas del receptor de glucocorticoides. | |
| MA37763A1 (fr) | Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 |